If small molecules immunotherapy comes, can the prime be far behind?

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Anti-cancer immunotherapy, including immune checkpoint blockade (ICB), has revolutionized cancer treatment.
• Current immune checkpoint inhibitors (ICIs) are monoclonal antibodies (mAbs) with limitations such as poor oral bioavailability and tissue penetration.
• The tumor micro-environment (TME) presents challenges for effective cancer immunotherapy.

Purpose of the Study:

• To review the mechanisms and therapeutic potential of small molecule inhibitors targeting cancer.
• To discuss the advantages of small molecule inhibitors over monoclonal antibodies in cancer immunotherapy.
• To summarize the current status of small molecule inhibitors in combination therapies for cancer.

Main Methods:

• Literature review of anti-cancer immunotherapy, focusing on immune checkpoint inhibitors.
• Analysis of the limitations of monoclonal antibody-based ICIs.
• Exploration of small molecule inhibitors as alternatives and their role in combination therapies.

Main Results:

• Small molecule inhibitors offer potential solutions to the limitations of mAbs, including improved bioavailability and permeability.
• Combination therapies involving ICIs and small molecule agents are under investigation to enhance treatment efficacy.
• Various molecular targets are being explored for small molecule inhibitor development in cancer treatment.

Conclusions:

• Small molecule inhibitors represent a promising advancement in anti-cancer immunotherapy, addressing key limitations of current antibody-based treatments.
• Further research and clinical trials are essential to fully realize the therapeutic potential of small molecule inhibitors, particularly in combination strategies.
• Targeting the TME with novel small molecule agents could lead to improved patient outcomes and reduced tumor recurrence.